Pebble Biotechnology Laboratories

Our next-generation LIVING-ORGAN systems support researchers in developing tangible healthcare products and innovations. Line-of-sight to patients is important to us and sits closely with our strong moral objective to improve patients lives. We progress an asset from a pipeline hypothesis through to clinical trial via three packages: Package 1 - FAST-TO-POC: Quick to fail/proceed analysis of a pre-pipeline asset with a focus on safety. De-risking investments and increasing confidence that an asset will proceed to an MHRA/EMA/FDA submission Package 2 - INTERNAL R&D in Stealth: Rapid generation of non reportable data of an asset - Detailed safety, immune profiling, organ-specific toxicities, evaluation of efficacy, on/off target effects. Enables commercially safe fail-iterate-repeat experiments Package 3 - MHRA/EMA/IND READY DATA: Preclinical Pharmacology and Toxicology Studies – to confirm an asset is reasonably safe for initial testing in humans. We are FASTER – We are a non-bureaucratic organisation. Our models do not need regulatory approval, meaning time-to-start is in days rather than months, resulting in high intensity data generation. We are responsive to data, allowing study designs to pivot and enabling highly iterative R&D. We are BETTER – We are a team of world leading experts with a collective experience in decades. Our technology is the most advanced in the world, only using state-of-the-art critical care equipment and MHRA/EMA/FDA approved tech. We are CHEAPER – On average we result in a 90% cost-saving compared to NHP in-vivo experiments. We act as your external ‘white-label’ R&D partner, significantly reducing your infrastructure costs and enabling a fee-per-project service. We are SECURE – We do not claim any IP related to your innovations. We serve a global market, with partners in the UK, Europe and America. Our team of data analysts and senior scientists provide a complete data package for 'stealth' R&D or clinical trial submission